Kopin Corporation 10-K Summary (Fiscal Year Ended Dec 31, 1998)
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 1998. Kopin Corporation is a developer and manufacturer of advanced semiconductor materials (specifically Gallium Arsenide or GaAs device wafers) and small form factor displays (CyberDisplay). The company utilizes proprietary "Wafer-Engineering" technology to splice semiconductor materials. Its primary customers include manufacturers of wireless communications equipment, with Conexant Systems, Inc. serving as the principal customer for GaAs products.
Key Financial Metrics
| Metric | 1998 | 1997 |
|---|---|---|
| Total Revenues | $26.9 million | $16.4 million |
| Product Revenues | $23.2 million | $13.1 million |
| Net Loss | $(2.97) million | $(6.26) million |
| Loss Per Share (Basic/Diluted) | $(0.25) | $(0.57) |
| Cash and Equivalents | $30.8 million | $14.4 million |
| Working Capital | $39.4 million | $21.5 million |
| Total Debt Obligations | $6.2 million | $3.5 million |
| Accumulated Deficit | $(57.5) million | $(54.5) million |
Margin Analysis: The company reported a gross margin on product revenues of approximately 33% in 1998 (calculated as Product Revenues of $23.2M less Cost of Product Revenues of $15.5M). This margin was impacted by a $1.7 million inventory write-down related to CyberDisplay process modifications.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 64% year-over-year, driven primarily by a 70% increase in GaAs product sales to $20.3 million. This growth was attributed to increased demand from Conexant for wireless telecommunications products.
- Profitability Improvement: Net loss narrowed significantly from $6.26 million in 1997 to $2.97 million in 1998. This improvement was aided by higher interest income ($2.04 million vs. $1.26 million) due to increased cash balances.
- Unusual Items: The company recorded a non-cash impairment charge of $1.8 million and an inventory write-down of approximately $1.7 million in 1998, both associated with modifying CyberDisplay manufacturing processes to improve flexibility.
- Liquidity: Cash and equivalents more than doubled to $30.8 million, bolstered by a $17.2 million public offering of common stock and a $5.0 million term loan facility secured by accounts receivable.
Guidance, Outlook, and Risks
Outlook: Management anticipates continued investment in equipment and development for CyberDisplay products, with an estimated $10 million in capital expenditures over the next twelve months. The company expects CyberDisplay products to be introduced in the second half of 1999. Research and development revenues are expected to decline as a percentage of total revenues as the company shifts focus to commercial product sales.
Risks and Contingencies:
- Customer Concentration: Sales to Conexant accounted for 59% of total revenues in 1998. A reduction in orders from this single customer would materially impact operations.
- Market Acceptance: The CyberDisplay product relies on a specific viewing format (lens and backlight) that requires widespread market adoption. There is no assurance that customers or end-users will accept this technology over traditional displays.
- Manufacturing Reliance: The company relies on third-party contractors (UMC and Unipac) for the fabrication and packaging of CyberDisplay products, introducing risks regarding capacity, quality, and delivery schedules.
- Profitability: The company has never achieved profitability and has an accumulated deficit of $57.5 million. Continued losses may require additional financing.
Investor Verification Checklist
- Conexant Dependency: Verify the stability of the relationship with Conexant, which represents the majority of revenue.
- CyberDisplay Commercialization: Confirm the timeline and initial order volumes for CyberDisplay products expected in late 1999.
- Cash Burn Rate: Assess whether the current cash balance of $30.8 million is sufficient to fund the projected $10 million in capital expenditures and ongoing R&D without further dilution.
- Inventory Valuation: Review the rationale and magnitude of the $1.7 million inventory write-down to ensure it does not signal deeper manufacturing issues.
- Debt Covenants: Examine the terms of the $5 million term loan secured by accounts receivable to understand potential liquidity constraints.